$CTCX
Carmell Corp

2024 Q2 Form 10-Q Financial Statement

#000095017024060506 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $12.32K $0.00 $0.00
YoY Change
Cost Of Revenue $292.00
YoY Change
Gross Profit $12.03K
YoY Change
Gross Profit Margin 97.63%
Selling, General & Admin $1.076M $927.4K $756.5K
YoY Change -7.25% 22.59% 41.36%
% of Gross Profit 8945.13%
Research & Development $104.1K $429.4K $740.3K
YoY Change -87.37% -42.0%
% of Gross Profit 865.2%
Depreciation & Amortization $23.53K $23.53K $24.10K
YoY Change -10.44% -2.37%
% of Gross Profit 195.63%
Operating Expenses $1.204M $1.380M $756.5K
YoY Change 3.75% 82.47% 41.36%
Operating Profit -$1.191M -$1.380M -$756.5K
YoY Change 2.58% 82.47% 41.36%
Interest Expense $3.264K -$11.57K $1.676M
YoY Change -99.83% -100.69% 21921.81%
% of Operating Profit
Other Income/Expense, Net -$2.113M -$2.173M -$553.8K
YoY Change -44.71% 292.32%
Pretax Income -$3.305M -$3.553M $919.4K
YoY Change -567.97% -486.47% -274.28%
Income Tax $0.00 $0.00 $343.3K
% Of Pretax Income 37.34%
Net Earnings -$3.305M -$3.271M $576.1K
YoY Change -1140.76% -667.81% -209.2%
Net Earnings / Revenue -26822.55%
Basic Earnings Per Share -$0.16 -$0.14 -$1.91
Diluted Earnings Per Share -$0.16 -$0.14 $0.03
COMMON SHARES
Basic Shares Outstanding 20.80M 19.25M 1.123M
Diluted Shares Outstanding 20.74M 22.92M 1.123M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.198M $892.2K $16.13K
YoY Change 5431.06% -97.29%
Cash & Equivalents $2.198M $892.2K $16.13K
Short-Term Investments
Other Short-Term Assets $1.584M $17.56K $111.1K
YoY Change 1484.3% -84.19% -31.16%
Inventory $113.9K
Prepaid Expenses $164.2K $531.3K $111.1K
Receivables
Other Receivables
Total Short-Term Assets $4.101M $5.189M $127.2K
YoY Change 6264.96% 3979.19% -83.17%
LONG-TERM ASSETS
Property, Plant & Equipment $148.0K $170.4K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $158.4M
YoY Change 2.53%
Other Assets
YoY Change
Total Long-Term Assets $932.8K $991.1K $158.4M
YoY Change -99.42% -99.37% 2.53%
TOTAL ASSETS
Total Short-Term Assets $4.101M $5.189M $127.2K
Total Long-Term Assets $932.8K $991.1K $158.4M
Total Assets $5.034M $6.180M $158.5M
YoY Change -96.86% -96.1% 2.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.095M $4.283M
YoY Change
Accrued Expenses $1.661M $1.891M $1.817M
YoY Change -41.0% 4.04% 180.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $21.29K $731.3K
YoY Change
Total Short-Term Liabilities $5.778M $6.906M $2.623M
YoY Change 40.57% 163.28% 304.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $628.0K $666.5K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $628.0K $666.5K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.778M $6.906M $2.623M
Total Long-Term Liabilities $628.0K $666.5K $0.00
Total Liabilities $6.406M $7.572M $2.623M
YoY Change 55.85% 188.69% -56.67%
SHAREHOLDERS EQUITY
Retained Earnings -$65.08M -$61.77M -$1.308M
YoY Change 2608.36% 4622.55%
Common Stock $2.091K $1.936K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.372M -$1.392M -$1.308M
YoY Change
Total Liabilities & Shareholders Equity $5.034M $6.180M $158.5M
YoY Change -96.86% -96.1% 2.12%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$3.305M -$3.271M $576.1K
YoY Change -1140.76% -667.81% -209.2%
Depreciation, Depletion And Amortization $23.53K $23.53K $24.10K
YoY Change -10.44% -2.37%
Cash From Operating Activities -$1.138M -$1.076M -$171.5K
YoY Change 11284.7% 527.16% 13.09%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$748.8K
YoY Change
Cash From Investing Activities $0.00 -$748.8K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.445M -195.7K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.138M -1.076M -171.5K
Cash From Investing Activities 0.000 -748.8K
Cash From Financing Activities 2.445M -195.7K 0.000
Net Change In Cash 1.306M -2.020M -171.5K
YoY Change -13161.2% 1077.8% -4.42%
FREE CASH FLOW
Cash From Operating Activities -$1.138M -$1.076M -$171.5K
Capital Expenditures $0.00
Free Cash Flow -$1.138M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001842939
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-40228
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
CARMELL CORPORATION
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-1645738
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2403 Sidney Street
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Pittsburgh
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
15203
CY2024Q1 dei City Area Code
CityAreaCode
919
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
313-9633
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
CTCX
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20803228
CY2024Q1 us-gaap Cash
Cash
892161
CY2023Q4 us-gaap Cash
Cash
2912461
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
531327
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
761271
CY2024Q1 ctcx Forward Purchase Agreement
ForwardPurchaseAgreement
3543614
CY2023Q4 ctcx Forward Purchase Agreement
ForwardPurchaseAgreement
5700451
CY2024Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
0
CY2023Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
53321372
CY2024Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
204559
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
204559
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
17563
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
0
CY2024Q1 us-gaap Assets Current
AssetsCurrent
5189224
CY2023Q4 us-gaap Assets Current
AssetsCurrent
62900114
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
645114
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
622714
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
170447
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
192846
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
797617
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
831656
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
47691
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
46559
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
23055
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
24187
CY2024Q1 us-gaap Assets
Assets
6180343
CY2023Q4 us-gaap Assets
Assets
63948803
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4283470
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4417234
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
1175845
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1175845
CY2024Q1 ctcx Accrued Expenses And Other Liabilities Excluding Interest Payable Current
AccruedExpensesAndOtherLiabilitiesExcludingInterestPayableCurrent
568345
CY2023Q4 ctcx Accrued Expenses And Other Liabilities Excluding Interest Payable Current
AccruedExpensesAndOtherLiabilitiesExcludingInterestPayableCurrent
1595434
CY2024Q1 us-gaap Loans Payable Current
LoansPayableCurrent
731340
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
1288598
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
146552
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
150136
CY2024Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
0
CY2023Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
29874831
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6905552
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38502078
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
666450
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
697715
CY2024Q1 us-gaap Liabilities
Liabilities
7572002
CY2023Q4 us-gaap Liabilities
Liabilities
39199793
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
1
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19361068
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19361068
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23090585
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23090585
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
1936
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2309
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60380765
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
83250101
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61774360
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58503401
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1391659
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
24749010
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6180343
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
63948803
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
429420
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
740325
CY2024Q1 ctcx Formation General And Administrative Expenses
FormationGeneralAndAdministrativeExpenses
927394
CY2023Q1 ctcx Formation General And Administrative Expenses
FormationGeneralAndAdministrativeExpenses
510445
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
23531
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
24101
CY2024Q1 us-gaap Restructuring Charges
RestructuringCharges
0
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
0
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
1380345
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
1274871
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1380345
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1274871
CY2024Q1 us-gaap Other Income
OtherIncome
9054
CY2023Q1 us-gaap Other Income
OtherIncome
34541
CY2024Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
11566
CY2023Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
262597
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
13468
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
703
CY2024Q1 ctcx Loss On Forward Purchase Agreement
LossOnForwardPurchaseAgreement
2156837
CY2023Q1 ctcx Loss On Forward Purchase Agreement
LossOnForwardPurchaseAgreement
0
CY2024Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0
CY2023Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-325085
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2172817
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-553844
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3553162
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1828715
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-3553162
CY2023Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-1828715
CY2024Q1 us-gaap Net Income Loss From Discontinued Operations Available To Common Shareholders Basic
NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic
-1252276
CY2023Q1 us-gaap Net Income Loss From Discontinued Operations Available To Common Shareholders Basic
NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic
0
CY2024Q1 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
1534479
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3270959
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1828715
CY2024Q1 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
0
CY2023Q1 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
311168
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3270959
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2139883
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.16
CY2024Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.16
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.91
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.91
CY2024Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
0.02
CY2024Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0.02
CY2023Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
0
CY2023Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.91
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.91
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22915160
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22915160
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1122529
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1122529
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-37790539
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
180509
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1828715
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-39743801
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
24749010
CY2024Q1 ctcx Stock Issued During Period Value In Connection With Conversion Of Promissory Notes
StockIssuedDuringPeriodValueInConnectionWithConversionOfPromissoryNotes
375000
CY2024Q1 ctcx Stock Received During Period Value From Disposition
StockReceivedDuringPeriodValueFromDisposition
-23456179
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
211469
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3270959
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1391659
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-3553162
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-1828715
CY2024Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-1252276
CY2024Q1 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
1534479
CY2024Q1 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-1534479
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
211469
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
180509
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
23531
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
24101
CY2024Q1 ctcx Operating Lease Right Of Use Asset Amortization Expense Reversal
OperatingLeaseRightOfUseAssetAmortizationExpenseReversal
34039
CY2023Q1 ctcx Operating Lease Right Of Use Asset Amortization Expense Reversal
OperatingLeaseRightOfUseAssetAmortizationExpenseReversal
35809
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
13468
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
703
CY2024Q1 ctcx Change In Fair Value Of Forward Purchase Agreement
ChangeInFairValueOfForwardPurchaseAgreement
2156837
CY2023Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-325085
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-229944
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-47826
CY2024Q1 us-gaap Increase Decrease In Assets Held For Sale
IncreaseDecreaseInAssetsHeldForSale
-4662980
CY2024Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
17563
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-11183
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-133764
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
159097
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1027089
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
337258
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-34849
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-31413
CY2023Q1 ctcx Increase Decrease In Acrrued Interest
IncreaseDecreaseInAcrruedInterest
262598
CY2024Q1 ctcx Increase Decrease In Liabilities Available For Sales
IncreaseDecreaseInLiabilitiesAvailableForSales
-2389343
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1075778
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-475959
CY2024Q1 us-gaap Cash Divested From Deconsolidation
CashDivestedFromDeconsolidation
748796
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-748796
CY2024Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
31538
CY2023Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
375000
CY2024Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
227264
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-195726
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
375000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2020300
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-100959
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2912461
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
128149
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
892161
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27190
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
11566
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
37037
CY2024Q1 ctcx Asset Sold In Acquisition Net
AssetSoldInAcquisitionNet
21921697
CY2024Q1 ctcx Fair Value Of Shares Received In Business Disposition
FairValueOfSharesReceivedInBusinessDisposition
23456179
CY2024Q1 ctcx Issuance Of Common Stock In Connection With Conversion Of Promissory Notes
IssuanceOfCommonStockInConnectionWithConversionOfPromissoryNotes
375000
CY2023Q1 ctcx Accrued Legacy Series A Preferred Stock Dividends
AccruedLegacySeriesAPreferredStockDividends
75084
CY2023Q1 ctcx Accrued Legacy Series C1 Preferred Stock Dividends
AccruedLegacySeriesC1PreferredStockDividends
18716
CY2023Q1 ctcx Accrued Legacy Series C2 Preferred Stock Dividends
AccruedLegacySeriesC2PreferredStockDividends
217368
CY2023Q1 ctcx Warrants Issued In Connection With Convertible Notes
WarrantsIssuedInConnectionWithConvertibleNotes
6112
CY2023Q1 ctcx Unpaid Deferred Offering Costs
UnpaidDeferredOfferingCosts
660426
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.28
CY2023Q3 us-gaap Temporary Equity Aggregate Amount Of Redemption Requirement
TemporaryEquityAggregateAmountOfRedemptionRequirement
29374372
CY2023Q3 us-gaap Assets Held In Trust
AssetsHeldInTrust
29376282
CY2023Q3 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.28
CY2023Q3 ctcx Termination Fee Payable Per Share
TerminationFeePayablePerShare
0.5
CY2024Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-3553162
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1075778
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these financial statements include</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">those </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">related to the forward purchase asset, earnout liabilities, derivative liabilities, long-term assets and goodwill impairment, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets, and contingent liabilities. If the underlying estimates and assumptions upon which the financial statements are based change in the future, actual amounts may differ from those included in the accompanying financial statements.</span></p>
CY2024Q1 ctcx Cash In Excess Of Federally Insured Limits
CashInExcessOfFederallyInsuredLimits
392161
CY2024Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
15107
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
30000
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2024Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
100000
CY2024Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2024Q1 us-gaap Income Tax Examination Year Under Examination
IncomeTaxExaminationYearUnderExamination
2018
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6176213
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12743684
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">One</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of AxoBio’s revenues in 2023 and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of its accounts receivable at December 31, 2023. AxoBio’s human amnion allograft product made up </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of revenue for the year ended December 31, 2023, which was all purchased from a single vendor, Pinnacle Transplant Technologies, LLC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
892161
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61774360
CY2024Q1 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
70746
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
3396
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
4516
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
4516
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
4090
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2451
CY2024Q1 ctcx Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
4086
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
23055
CY2024Q1 ctcx Number Of Office Leases
NumberOfOfficeLeases
2
CY2024Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2028-12-31
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
50423
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
50423
CY2024Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2024Q1 us-gaap Lease Cost
LeaseCost
50423
CY2023Q1 us-gaap Lease Cost
LeaseCost
52446
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
34839
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
31413
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
153698
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
204930
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
204930
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
204930
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
204930
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
973418
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
160416
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
813002
CY2024Q1 us-gaap Description Of Defined Contribution Pension And Other Postretirement Plans
DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
The Company has 401(k) profit-sharing plans covering substantially all employees. The Company’s discretionary profit-sharing contributions are determined annually by the Board. No discretionary profit-sharing contributions were made to the plans during the three months ended March 31, 2024 and 2023.
CY2024Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2023Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19361068
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1689765
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.72
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1850397
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
70000
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.57
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
386254
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
2.9
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1373511
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.71
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M8D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
193527
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
332737
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.16
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
149501
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.70
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.038
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.043
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
211469
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
180509
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1765553
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1765553
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M29D
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ctcx Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q1 ctcx Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false

Files In Submission

Name View Source Status
0000950170-24-060506-index-headers.html Edgar Link pending
0000950170-24-060506-index.html Edgar Link pending
0000950170-24-060506.txt Edgar Link pending
0000950170-24-060506-xbrl.zip Edgar Link pending
ctcx-20240331.htm Edgar Link pending
ctcx-20240331.xsd Edgar Link pending
ctcx-ex31_1.htm Edgar Link pending
ctcx-ex31_2.htm Edgar Link pending
ctcx-ex32_1.htm Edgar Link pending
ctcx-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ctcx-20240331_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending